trending Market Intelligence /marketintelligence/en/news-insights/trending/v4cmtcl_xk_2ln6yby5imq2 content esgSubNav
In This List

Pfizer breast cancer drug accepted for US FDA, EMA review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer breast cancer drug accepted for US FDA, EMA review

Pfizer Inc. said the U.S. Food and Drug Administration accepted the new drug application for its breast cancer drug talazoparib.

The U.S. regulator also granted priority review designation to the drug, which is intended to treat patients with inherited BRCA-mutated HER2-negative breast cancer that has grown outside the organ or has spread to other parts of the body.

Priority review designation is granted to drugs that may offer a significant benefit in treatment or may provide treatment for a disease which has no adequate therapy.

The FDA expects to take a decision on the application in December.

In addition, the European Medicines Agency accepted the marketing authorization application for talazoparib in the same patient population, the New York-based drug developer said.

The submissions were based on results from a phase 3 study, named EMBRACA, which compared talazoparib with chemotherapy and showed extended survival in breast cancer patients.

SNL Image